Clinical Use of Creatine in Neuromuscular and Neurometabolic Disorders

  • Mark A. Tarnopolsky
Part of the Subcellular Biochemistry book series (SCBI, volume 46)


Many of the neuromuscular (e.g., muscular dystrophy) and neurometabolic (e.g., mitochondrial cytopathies) disorders share similar final common pathways of cellular dysfunction that may be favorably influenced by creatine monohydrate (CrM) supplementation. Studies using the mdx model of Duchenne muscular dystrophy have found evidence of enhanced mitochondrial function, reduced intra-cellular calcium and improved performance with CrM supplementation. Clinical trials in patients with Duchenne and Becker’s muscular dystrophy have shown improved function, fat-free mass, and some evidence of improved bone health with CrM supplementation. In contrast, the improvements in function in myotonic dystrophy and inherited neuropathies (e.g., Charcot-Marie-Tooth) have not been significant. Some studies in patients with mitochondrial cytopathies have shown improved muscle endurance and body composition, yet other studies did not find significant improvements in patients with mitochondrial cytopathy. Lower-dose CrM supplementation in patients with McArdle’s disease (myophosphorylase deficiency) improved exercise capacity, yet higher doses actually showed some indication of worsened function. Based upon known cellular pathologies, there are potential benefits from CrM supplementation in patients with steroid myopathy, inflammatory myopathy, myoadenylate deaminase deficiency, and fatty acid oxidation defects. Larger randomized control trials (RCT) using homogeneous patient groups and objective and clinically relevant outcome variables are needed to determine whether creatine supplementation will be of therapeutic benefit to patients with neuromuscular or neurometabolic disorders. Given the relatively low prevalence of some of the neuromuscular and neurometabolic disorders, it will be necessary to use surrogate markers of potential clinical efficacy including markers of oxidative stress, cellular energy charge, and gene expression patterns


Muscular Dystrophy Lipoic Acid Duchenne Muscular Dystrophy Creatine Supplementation Inclusion Body Myositis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adcock, K.H., Nedelcu, J., Loenneker, T., Martin, E., Wallimann, T., and Wagner, B.P., 2002, Neuroprotection of creatine supplementation in neonatal rats with transient cerebral hypoxia-ischemia. Dev. Neurosci. 24: 382–388.CrossRefPubMedGoogle Scholar
  2. Alexanderson, H., 2005, Exercise: an important component of treatment in the idiopathic inflammatory myopathies. Curr, Rheumatol. Rep. 7: 115–124.CrossRefGoogle Scholar
  3. Andreassen, O.A., Dedeoglu, A., Ferrante, R.J., Jenkins, B.G., Ferrante, K.L., Thomas, M., Friedlich, A., Browne, S.E., Schilling, G., Borchelt, D.R., Hersch, S.M., Ross, C.A., and Beal, M.F., 2001, Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington’s disease. Neurobiol. Dis. 8: 479–491.CrossRefPubMedGoogle Scholar
  4. Argov, Z., De Stefano, N., and Arnold, D.L., 1996, ADP recovery after a brief ischemic exercise in normal and diseased human muscle – a 31P MRS study. NMR Biomed. 9: 165–172.CrossRefPubMedGoogle Scholar
  5. Arnardottir, S., Alexanderson, H., Lundberg, I.E., and Borg, K., 2003, Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J. Rehabil. Med. 35: 31–35.CrossRefPubMedGoogle Scholar
  6. Baker, S.K., and Tarnopolsky, M.A., 2001, Statin myopathies: pathophysiologic and clinical perspectives. Clin. Invest. Med. 24: 258–272.PubMedGoogle Scholar
  7. Baker, S.K., and Tarnopolsky, M.A., 2003, Targeting cellular energy production in neurological disorders. Expert Opin. Investig. Drugs 12: 1655–1679.CrossRefPubMedGoogle Scholar
  8. Baker, S.K., and Tarnopolsky, M.A., 2005, Statin-associated neuromyotoxicity. Drugs Today (Barc.) 41: 267–293.CrossRefGoogle Scholar
  9. Barisic, N., Bernert, G., Ipsiroglu, O., Stromberger, C., Muller, T., Gruber, S., Prayer, D., Moser, E., Bittner, R.E., and Stöckler-Ipsiroglu, S., 2002, Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy. Neuropediatrics 33: 157–161.CrossRefPubMedGoogle Scholar
  10. Benedict, J.D., Kalinsky, H.J., Scarrone, L.A., Wertbeim, A.R., and Stetten, D., Jr., 1955, The origin of urinary creatine in progressive muscular dystrophy. J. Clin. Invest. 34: 141–145.PubMedGoogle Scholar
  11. Borchert, A., Wilichowski, E., and Hanefeld, F., 1999, Supplementation with creatine monohydrate in children with mitochondrial encephalomyopathies. Muscle Nerve 22: 1299–1300.CrossRefPubMedGoogle Scholar
  12. Brooke, M.H., Fenichel, G.M., Griggs, R.C., Mendell, J.R., Moxley, R., Florence, J., King, W.M., Pandya, S., Robison, J., Schierbecker, J., et al., 1989, Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 39: 475–481.PubMedGoogle Scholar
  13. Brooke, M.H., Griggs, R.C., Mendell, J.R., Fenichel, G.M., and Shumate, J.B., 1981a, The natural history of Duchenne muscular dystrophy: a caveat for therapeutic trials. Trans. Am. Neurol. Assoc. 106: 195–199.Google Scholar
  14. Brooke, M.H., Griggs, R.C., Mendell, J.R., Fenichel, G.M., Shumate, J.B., and Pellegrino, R.J., 1981b, Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 4: 186–197.CrossRefGoogle Scholar
  15. Brose, A., Parise, G., and Tarnopolsky, M.A., 2003, Creatine supplementation enhances isometric strength and body composition improvements following strength exercise training in older adults. J. Gerontol. A Biol. Sci. Med. Sci. 58: 11–19.PubMedGoogle Scholar
  16. Burke, D.G., Chilibeck, P.D., Parise, G., Candow, D.G., Mahoney, D., and Tarnopolsky, M., 2003a, Effect of creatine and weight training on muscle creatine and performance in vegetarians. Med. Sci. Sports Exerc. 35: 1946–1955.CrossRefGoogle Scholar
  17. Burke, D.G., Chilibeck, P.D., Parise, G., Tarnopolsky, M.A., and Candow, D.G., 2003b, Effect of alpha-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration. Int. J. Sport Nutr. Exerc. Metab. 13: 294–302.Google Scholar
  18. Campos, A.R., Serafini, L.N., Sobreira, C., Menezes, L.G., and Martinez, J.A., 2006, Creatine intake attenuates corticosteroid-induced impairment of voluntary running in hamsters. Appl. Physiol. Nutr. Metab. 31: 490–494.CrossRefPubMedGoogle Scholar
  19. Carter, A.J., Muller, R.E., Pschorn, U., and Stransky, W., 1995, Preincubation with creatine enhances levels of creatine phosphate and prevents anoxic damage in rat hippocampal slices. J. Neurochem. 64: 2691–2699.PubMedCrossRefGoogle Scholar
  20. Casey, A., Constantin-Teodosiu, D., Howell, S., Hultman, E., and Greenhaff, P.L., 1996, Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Am. J. Physiol. 271: E31–E37.PubMedGoogle Scholar
  21. Chang, C.T., Wu, C.H., Yang, C.W., Huang, J.Y., and Wu, M.S., 2002, Creatine monohydrate treatment alleviates muscle cramps associated with haemodialysis. Nephrol. Dial. Transplant. 17: 1978–1981.CrossRefPubMedGoogle Scholar
  22. Chetlin, R.D., Gutmann, L., Tarnopolsky, M.A., Ullrich, I.H., and Yeater, R.A., 2004, Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease. Muscle Nerve 30: 69–76.CrossRefPubMedGoogle Scholar
  23. Chilibeck, P.D., Chrusch, M.J., Chad, K.E., Shawn Davison, K., and Burke, D.G., 2005, Creatine monohydrate and resistance training increase bone mineral content and density in older men. J. Nutr. Health Aging 9: 352–353.PubMedGoogle Scholar
  24. Dedeoglu, A., Kubilus, J.K., Yang, L., Ferrante, K.L., Hersch, S.M., Beal, M.F., and Ferrante, R.J., 2003, Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington’s disease transgenic mice. J. Neurochem. 85: 1359–1367.CrossRefPubMedGoogle Scholar
  25. Doherty, T.J., Lougheed, K., Markez, J., and Tarnopolsky, M.A., 2001, Creatine monohydrate does not increase strength in patients with hereditary neuropathy. Neurology 57: 559–560.PubMedGoogle Scholar
  26. Duke, A.M., and Steele, D.S., 1999, Effects of creatine phosphate on Ca2+ regulation by the sarcoplasmic reticulum in mechanically skinned rat skeletal muscle fibres. J. Physiol. 517: 447–458.CrossRefPubMedGoogle Scholar
  27. Escolar, D.M., Buyse, G., Henricson, E., Leshner, R., Florence, J., Mayhew, J., Tesi-Rocha, C., Gorni, K., Pasquali, L., Patel, K.M., McCarter, R., Huang, J., Mayhew, T., Bertorini, T., Carlo, J., Connolly, A.M., Clemens, P.R., Goemans, N., Iannaccone, S.T., Igarashi, M., Nevo, Y., Pestronk, A., Subramony, S.H., Vedanarayanan, V.V., and Wessel, H., 2005, CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann. Neurol. 58: 151–155.CrossRefPubMedGoogle Scholar
  28. Escolar, D.M., Henricson, E.K., Mayhew, J., Florence, J., Leshner, R., Patel, K.M., and Clemens, P.R., 2001, Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children. Muscle Nerve 24: 787–793.CrossRefPubMedGoogle Scholar
  29. Gerber, I., ap Gwynn, I., Alini, M., and Wallimann, T., 2005, Stimulatory effects of creatine on metabolic activity, differentiation and mineralization of primary osteoblast-like cells in monolayer and micromass cell cultures. Eur. Cells Mater. 10: 8–22.Google Scholar
  30. Gordon, A., Hultman, E., Kaijser, L., Kristjansson, S., Rolf, C.J., Nyquist, O., and Sylven, C., 1995, Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc. Res. 30: 413–418.CrossRefPubMedGoogle Scholar
  31. Granchelli, J.A., Pollina, C., and Hudecki, M.S., 2000, Pre-clinical screening of drugs using the mdx mouse. Neuromusc. Disord. 10: 235–239.CrossRefPubMedGoogle Scholar
  32. Hespel, P., Op’t Eijnde, B., and Van Leemputte, M., 2002, Opposite actions of caffeine and creatine on muscle relaxation time in humans. J. Appl. Physiol. 92: 513–518.PubMedGoogle Scholar
  33. Isenberg, D.A., Allen, E., Farewell, V., Ehrenstein, M.R., Hanna, M.G., Lundberg, I.E., Oddis, C., Pilkington, C., Plotz, P., Scott, D., Vencovsky, J., Cooper, R., Rider, L., and Miller, F., 2004, International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43: 49–54.CrossRefGoogle Scholar
  34. Johansen, K.L., Doyle, J., Sakkas, G.K., and Kent-Braun, J.A., 2005, Neural and metabolic mechanisms of excessive muscle fatigue in maintenance hemodialysis patients. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289: R805–R813.PubMedGoogle Scholar
  35. Klein, A.M., and Ferrante, R.J., 2007, The neuroprotective role of creatine. Subcell. Biochem. 46: 205–243.CrossRefPubMedGoogle Scholar
  36. Kley, R., Vorgerd, M., and Tarnopolsky, M., 2007, Creatine for treating muscle disorders. Cochrane Database Syst. Rev. CD004760.Google Scholar
  37. Klivenyi, P., Calingasan, N.Y., Starkov, A., Stavrovskaya, I.G., Kristal, B.S., Yang, L., Wieringa, B., and Beal, M.F., 2004, Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiol. Dis. 15: 610–617.CrossRefPubMedGoogle Scholar
  38. Klivenyi, P., Ferrante, R.J., Matthews, R.T., Bogdanov, M.B., Klein, A.M., Andreassen, O.A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., and Beal, M.F., 1999, Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5: 347–350.CrossRefPubMedGoogle Scholar
  39. Klopstock, T., Querner, V., Schmidt, F., Gekeler, F., Walter, M., Hartard, M., Henning, M., Gasser, T., Pongratz, D., Straube, A., Dieterich, M., and Muller-Felber, W., 2000, A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 55: 1748–1751.PubMedGoogle Scholar
  40. Komura, K., Hobbiebrunken, E., Wilichowski, E.K., and Hanefeld, F.A., 2003, Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr. Neurol. 28: 53–58.CrossRefPubMedGoogle Scholar
  41. Korenke, G.C., Wanders, R.J., and Hanefeld, F., 2003, Striking improvement of muscle strength under creatine therapy in a patient with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. J. Inherit. Metab. Dis. 26: 67–68.CrossRefPubMedGoogle Scholar
  42. Kornblum, C., Schroder, R., Muller, K., Vorgerd, M., Eggers, J., Bogdanow, M., Papassotiropoulos, A., Fabian, K., Klockgether, T., and Zange, J., 2005, Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study. Eur. J. Neurol. 12: 300–309.CrossRefPubMedGoogle Scholar
  43. Kuethe, F., Krack, A., Richartz, B.M., and Figulla, H.R., 2006, Creatine supplementation improves muscle strength in patients with congestive heart failure. Pharmazie 61: 218–222.PubMedGoogle Scholar
  44. Lawler, J.M., Barnes, W.S., Wu, G., Song, W., and Demaree, S., 2002, Direct antioxidant properties of creatine. Biochem. Biophys. Res. Commun. 290: 47–52.CrossRefPubMedGoogle Scholar
  45. Louis, M., Lebacq, J., Poortmans, J.R., Belpaire-Dethiou, M.C., Devogelaer, J.P., Van Hecke, P., Goubel, F., and Francaux, M., 2003, Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve 27: 604–610.CrossRefPubMedGoogle Scholar
  46. Louis, M., Raymackers, J.M., Debaix, H., Lebacq, J., and Francaux, M., 2004, Effect of creatine supplementation on skeletal muscle of mdx mice. Muscle Nerve 29: 687–692.CrossRefPubMedGoogle Scholar
  47. Mahoney, D.J., Parise, G., and Tarnopolsky, M.A., 2002, Nutritional and exercise-based therapies in the treatment of mitochondrial disease. Curr. Opin. Clin. Nutr. Metab. Care 5: 619–629.CrossRefPubMedGoogle Scholar
  48. Malcon, C., Kaddurah-Daouk, R., and Beal, M.F., 2000, Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Res. 860: 195–198.CrossRefPubMedGoogle Scholar
  49. Mallouk, N., Jacquemond, V., and Allard, B., 2000, Elevated subsarcolemmal Ca2+ in mdx mouse skeletal muscle fibers detected with Ca2+-activated K+ channels. Proc. Natl. Acad. Sci. USA 97: 4950–4955.CrossRefPubMedGoogle Scholar
  50. Menezes, L.G., Sobreira, C., Neder, L., Rodrigues-Junior, A.L., and Martinez, J.A., 2007, Creatine supplementation attenuates corticosteroid-induced muscle wasting and impairment of exercise performance in rats. J. Appl. Physiol. 102: 698–703.CrossRefPubMedGoogle Scholar
  51. Mihic, S., MacDonald, J.R., McKenzie, S., and Tarnopolsky, M.A., 2000, Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. Med. Sci. Sports Exerc. 32: 291–296.CrossRefPubMedGoogle Scholar
  52. Milhorat, A.T., 1953, Creatine and creatinine metabolism and diseases of the neuromuscular system. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 32: 400–421.PubMedGoogle Scholar
  53. Moxley, R.T., 3rd, Ashwal, S., Pandya, S., Connolly, A., Florence, J., Mathews, K., Baumbach, L., McDonald, C., Sussman, M., and Wade, C., 2005, Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 64: 13–20.PubMedGoogle Scholar
  54. Parise, G., Mihic, S., MacLennan, D., Yarasheski, K.E., and Tarnopolsky, M.A., 2001, Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. J. Appl. Physiol. 91: 1041–1047.PubMedGoogle Scholar
  55. Park, J.H., Niermann, K.J., Ryder, N.M., Nelson, A.E., Das, A., Lawton, A.R., Hernanz-Schulman, M., and Olsen, N.J., 2000, Muscle abnormalities in juvenile dermatomyositis patients: P-31 magnetic resonance spectroscopy studies. Arthritis Rheum. 43: 2359–2367.CrossRefPubMedGoogle Scholar
  56. Park, J.H., Olsen, N.J., King, L., Jr., Vital, T., Buse, R., Kari, S., Hernanz-Schulman, M., and Price, R.R., 1995, Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. Arthritis Rheum. 38: 68–77.CrossRefPubMedGoogle Scholar
  57. Park, J.H., Vital, T.L., Ryder, N.M., Hernanz-Schulman, M., Partain, C.L., Price, R.R., and Olsen, N.J., 1994, Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum. 37: 736–746.CrossRefPubMedGoogle Scholar
  58. Passaquin, A.C., Renard, M., Kay, L., Challet, C., Mokhtarian, A., Wallimann, T., and Ruegg, U.T., 2002, Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromusc. Disord. 12: 174–182.CrossRefPubMedGoogle Scholar
  59. Payne, E.T., Yasuda, N., Bourgeois, J.M., Devries, M.C., Rodriguez, M.C., Yousuf, J., and Tarnopolsky, M.A., 2006, Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve 33: 66–77.CrossRefPubMedGoogle Scholar
  60. Piccolo, G., Banfi, P., Azan, G., Rizzuto, R., Bisson, R., Sandona, D., and Bellomo, G., 1991, Biological markers of oxidative stress in mitochondrial myopathies with progressive external ophthalmoplegia. J. Neurol. Sci. 105: 57–60.CrossRefPubMedGoogle Scholar
  61. Pulido, S.M., Passaquin, A.C., Leijendekker, W.J., Challet, C., Wallimann, T., and Ruegg, U.T., 1998, Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. FEBS Lett. 439: 357–362.CrossRefPubMedGoogle Scholar
  62. Raha, S., and Robinson, B.H., 2000, Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem. Sci. 25: 502–508.CrossRefPubMedGoogle Scholar
  63. Rindfleisch, J.A., and Muller, D., 2005, Diagnosis and management of rheumatoid arthritis. Am. Fam. Physician 72: 1037–1047.PubMedGoogle Scholar
  64. Rodriguez, M.C., MacDonald, J.R., Mahoney, D.J., Parise, G., Beal, M.F., and Tarnopolsky, M.A., 2007, Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 35: 235–242.CrossRefPubMedGoogle Scholar
  65. Roy, B.D., Bourgeois, J.M., Mahoney, D.J., and Tarnopolsky, M.A., 2002, Dietary supplementation with creatine monohydrate prevents corticosteroid-induced attenuation of growth in young rats. Can. J. Physiol. Pharmacol. 80: 1008–1014.CrossRefPubMedGoogle Scholar
  66. Scaglia, F., Towbin, J.A., Craigen, W.J., Belmont, J.W., Smith, E.O., Neish, S.R., Ware, S.M., Hunter, J.V., Fernbach, S.D., Vladutiu, G.D., Wong, L.J., and Vogel, H., 2004, Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 114: 925–931.CrossRefPubMedGoogle Scholar
  67. Schneider-Gold, C., Beck, M., Wessig, C., George, A., Kele, H., Reiners, K., and Toyka, K.V., 2003, Creatine monohydrate in DM2/PROMM: a double-blind placebo-controlled clinical study. Proximal myotonic myopathy. Neurology 60: 500–502.CrossRefPubMedGoogle Scholar
  68. Schneider-Gold, C., Gajdos, P., Toyka, K.V., and Hohlfeld, R.R., 2005, Corticosteroids for myasthenia gravis. Cochrane Database Syst. Rev. CD002828.Google Scholar
  69. Smith, C.A., Chetlin, R.D., Gutmann, L., Yeater, R.A., and Alway, S.E., 2006, Effects of exercise and creatine on myosin heavy chain isoform composition in patients with Charcot-Marie-Tooth disease. Muscle Nerve 34: 586–594.CrossRefPubMedGoogle Scholar
  70. Sullivan, P.G., Geiger, J.D., Mattson, M.P., and Scheff, S.W., 2000, Dietary supplement creatine protects against traumatic brain injury. Ann. Neurol. 48: 723–729.CrossRefPubMedGoogle Scholar
  71. Taivassalo, T., and Haller, R.G., 2005, Exercise and training in mitochondrial myopathies. Med. Sci. Sports Exerc. 37: 2094–2101.CrossRefPubMedGoogle Scholar
  72. Tarnopolsky, M.A., Roy, B.D., and MacDonald, J.R., 1997, A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 20: 1502–1509.CrossRefPubMedGoogle Scholar
  73. Tarnopolsky, M., and Martin, J., 1999, Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 52: 854–857.PubMedGoogle Scholar
  74. Tarnopolsky, M.A., and Parise, G., 1999, Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle Nerve 22: 1228–1233.CrossRefPubMedGoogle Scholar
  75. Tarnopolsky, M.A., Parise, G., Yardley, N.J., Ballantyne, C.S., Olatinji, S., and Phillips, S.M., 2001, Creatine-dextrose and protein-dextrose induce similar strength gains during training. Med. Sci. Sports Exerc. 33: 2044–2052.CrossRefPubMedGoogle Scholar
  76. Tarnopolsky, M.A., and Beal, M.F., 2001, Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. 49: 561–574.CrossRefPubMedGoogle Scholar
  77. Tarnopolsky, M., Parise, G., Fu, M.H., Brose, A., Parshad, A., Speer, O., and Wallimann, T., 2003, Acute and moderate-term creatine monohydrate supplementation does not affect creatine transporter mRNA or protein content in either young or elderly humans. Mol. Cell. Biochem. 244: 159–166.CrossRefPubMedGoogle Scholar
  78. Tarnopolsky, M., 2004, Exercise testing as a diagnostic entity in mitochondrial myopathies. Mitochondrion 4: 529–542.CrossRefPubMedGoogle Scholar
  79. Tarnopolsky, M., Mahoney, D., Thompson, T., Naylor, H., and Doherty, T.J., 2004a, Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1. Muscle Nerve 29: 51–58.CrossRefGoogle Scholar
  80. Tarnopolsky, M.A., Mahoney, D.J., Vajsar, J., Rodriguez, C., Doherty, T.J., Roy, B.D., and Biggar, D., 2004b, Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 62: 1771–1777.Google Scholar
  81. Tarnopolsky, M.A., Simon, D.K., Roy, B.D., Chorneyko, K., Lowther, S.A., Johns, D.R., Sandhu, J.K., Li, Y., and Sikorska, M., 2004c, Attenuation of free radical production and paracrystalline inclusions by creatine supplementation in a patient with a novel cytochrome b mutation. Muscle Nerve 29: 537–547.CrossRefGoogle Scholar
  82. Tarnopolsky, M.A., and Raha, S., 2005, Mitochondrial myopathies: diagnosis, exercise intolerance, and treatment options. Med. Sci. Sports Exerc. 37: 2086–2093.CrossRefPubMedGoogle Scholar
  83. Tartaglia, M.C., Chen, J.T., Caramanos, Z., Taivassalo, T., Arnold, D.L., and Argov, Z., 2000, Muscle phosphorus magnetic resonance spectroscopy oxidative indices correlate with physical activity. Muscle Nerve 23: 175–181.CrossRefPubMedGoogle Scholar
  84. Terjung, R.L., Clarkson, P., Eichner, E.R., Greenhaff, P.L., Hespel, P.J., Israel, R.G., Kraemer, W.J., Meyer, R.A., Spriet, L.L., Tarnopolsky, M.A., Wagenmakers, A.J., and Williams, M.H., 2000, American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation. Med. Sci. Sports Exerc. 32: 706–717.CrossRefPubMedGoogle Scholar
  85. Vorgerd, M., Grehl, T., Jager, M., Muller, K., Freitag, G., Patzold, T., Bruns, N., Fabian, K., Tegenthoff, M., Mortier, W., Luttmann, A., Zange, J., and Malin, J.P., 2000, Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. Arch. Neurol. 57: 956–963.CrossRefPubMedGoogle Scholar
  86. Vorgerd, M., Zange, J., Kley, R., Grehl, T., Husing, A., Jager, M., Muller, K., Schroder, R., Mortier, W., Fabian, K., Malin, J.P., and Luttmann, A., 2002, Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study. Arch. Neurol. 59: 97–101.CrossRefPubMedGoogle Scholar
  87. Whittingham, T.S., and Lipton, P., 1981, Cerebral synaptic transmission during anoxia is protected by creatine. J. Neurochem. 37: 1618–1621.CrossRefPubMedGoogle Scholar
  88. Wilken, B., Ramirez, J.M., Probst, I., Richter, D.W., and Hanefeld, F., 2000, Anoxic ATP depletion in neonatal mice brainstem is prevented by creatine supplementation. Arch. Dis. Child. Fetal Neonatal Ed. 82: F224–F227.CrossRefPubMedGoogle Scholar
  89. Zhu, S., Li, M., Figueroa, B.E., Liu, A., Stavrovskaya, I.G., Pasinelli, P., Beal, M.F., Brown, R.H., Jr., Kristal, B.S., Ferrante, R.J., and Friedlander, R.M., 2004, Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J. Neurosci. 24: 5909–5912.CrossRefPubMedGoogle Scholar
  90. Ziegler, D., 2004, Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review.Treat. Endocrinol. 3: 173–189.Google Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • Mark A. Tarnopolsky
    • 1
  1. 1.Department of Pediatrics and Medicine (Neurology and Rehabilitation), Neuromuscular and Neurometabolic Clinic, Rm 2H26McMaster University Medical CenterOntarioCanada,L8N 3Z5

Personalised recommendations